{"disease":{"id":"orr-os-pfs","name":"orr os pfs"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06925243","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":682,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT06949033","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":668,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT07450040","title":"Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":60,"lead_sponsor_name":"Eye & ENT Hospital of Fudan University","has_results":false},{"nct_id":"NCT07328802","title":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06574958","title":"Clinical Study of CD38\\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"The Second Hospital of Shandong University","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}